Tele: 561.316.3330
Breaking Medical Device News

Monday, October 18, 2021
HomeMEDTRONIC plcStatement from Medtronic Regarding FDA Circulatory System Devices Panel

Statement from Medtronic Regarding FDA Circulatory System Devices Panel

June 21, 2019

Statement from Medtronic was issued today regarding the U.S. Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee on paclitaxel-coated therapies in patients with peripheral artery disease in the superficial femoropopliteal artery.

Medtronic reports: Patient safety is our top priority – and has been since our company’s founding more than 60 years ago. These panel deliberations are critically important as the Food and Drug Administration (FDA), societies, physicians, and industry consider and address the recent questions around the safety of paclitaxel devices in peripheral arterial disease (PAD) above-the-knee. As an industry leader, we take our responsibility to patients and physicians very seriously and look forward to further collaboration on a response to the panel’s recommended next steps.

The Medtronic presentation included the independent, patient-level analysis from our two randomized controlled trials (RCTs)-IN.PACT SFA and IN.PACT Japan. This analysis also accounts for vital status data on 97 percent of patients from our RCTs, representing the highest rate obtained across all industry clinical data presented at the panel. Results demonstrate:

  • No drug-related mechanism for observed transient mortality signal
  • No observed dose relationship with mortality
  • No pattern of adverse events or cause of death to suggest unifying mechanism
  • No relatedness between deaths and paclitaxel, as adjudicated by a newly convened independent Clinical Events Committee (CEC) with paclitaxel toxicity expertise

Additionally, Peter A. Schneider, M.D., professor of Surgery, Division of Vascular & Endovascular Surgery, University of California San Francisco and principal investigator of the IN.PACT SFA trial, presented the clinical benefit of IN.PACT Admiral. In the IN.PACT SFA trial, three out of four DCB patients remained intervention-free through five years, and for DCB patients who required a repeat procedure, the time to reintervention was prolonged for more than two years. Medtronic remains confident that the IN.PACT Admiral benefit-risk profile is positive and supports IN.PACT Admiral DCB as a first-line strategy for the treatment of PAD.

The panel presentations and deliberations addressed a wide range of considerations related to paclitaxel drug-coated balloons (DCB) and drug-eluting stents (DES). Laura Mauri, M.D., vice president, Global Clinical Research & Analytics, Medtronic also presented alongside Dan Clair, M.D., chair of the Department of Surgery for the University of South Carolina (USC) and the Palmetto Health-USC Medical Group and Eric A. Secemsky, M.D., MSc, RPVI, FACC, FVSM, Beth Israel Deaconess Medical Center, Harvard Medical as part of an unprecedented pan-industry presentation.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Insulet Announces Board of Director Changes with Appointment of Luciana Borio, M.D. and Retirement of Sally W. Crawford

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced...

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

By using this website you agree to accept Medical Device News Magazine Privacy Policy